Elucent Medical is celebrating the performance of more than 25,000 successful procedures using its EnVisio In-Body Spatial Intelligence platform.
EnVisio, developed by the medical technology company headquartered in Eden Prairie, is a surgical guidance technology designed to transform breast cancer surgery by improving visibility, enhancing precision, and streamlining workflows.
“Behind every number is a patient who deserves the best care possible,” said Jason Pesterfield, CEO of Elucent. “Reaching 25,000 procedures highlights the trust surgeons have in our technology and reinforces our mission to support patients during one of the most critical times in their lives.”
Engineered with both clinicians and patients in mind, the EnVisio platform uses a wire- and radiation-free SmartClip, a small, permanently implantable soft tissue marker placed under image guidance prior to surgery, which allows for scheduling flexibility and enhanced patient comfort.
Additionally, according to Elucent, standard surgical instruments are transformed into smart tools that enhance surgical workflow without interruption, allowing surgical precision. Continuous true 3D surgical awareness provides distance, depth, and direction from the tip of the smart tool to the SmartClip marker in real time.
“As the first surgeon to use the EnVisio System, I’ve watched this technology evolve and improve,” said Dr. Dana Henkel, breast surgeon at SSM Health St. Mary’s Hospital-Madison. “The fact that it’s now used in 25,000 cases speaks volumes about its reliability, usability, and clinical value.”
Comments
We offer several ways for our readers to provide feedback. Your comments are welcome on our social media posts (Facebook, X, Instagram, Threads, and LinkedIn). We also encourage Letters to the Editor; submission guidelines can be found on our Contact Us page. If you believe this story has an error or you would like to get in touch with the author, please connect with us.